New knee shot aims to ease arthritis pain in early trial
NCT ID NCT07652372
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests an experimental drug called RAB001, given as an injection into the knee joint, for people with knee osteoarthritis. The study includes 60 participants aged 40 to 75 who have persistent knee pain despite conservative treatments. Researchers are primarily checking safety and how the drug moves through the body, while also looking for signs of pain relief and improved function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RAB001
What this could lead to
If it works, this could point toward a new injection to ease pain and improve knee function in people with osteoarthritis.
What could go wrong
This is a very early Phase 1 trial with only 60 people, focused on safety. It may not show clear benefit, and higher doses could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KNEE OSTEOARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijin, Beijin, 100730, China
-
The Third Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050051, China